ONC201 in recurrent high-grade glioma

ONC201 in recurrent high-grade glioma
Recruiting
18 years - 99 years
All
Phase 2
5 participants needed
1 Location

Brief description of study

This is a phase II, open-label study of ONC201 in adults with recurrent high- grade glioma. Subjects for this study will be recruited from the patient population that present to the Penn Brain tumor center- Department of Neurosurgery or Department of Medicine division of Hematology/ Oncology for evaluation and treatment of their brain tumors.

Subjects will be age 18 or older with a histone H3 K27M mutant glioma that has progressed after radiation therapy. The primary objective is to estimate the overall response rate (ORR) of ONC201 in this population.

In addition, secondary objects will be to assess the safety, toxicities and tolerability of ONC201 in adults with recurrent high-grade glioma and estimate the median PFS, PFS at 2 and 6 months (progression-free survival at 6 months), median OS, and median duration of response. This study is sponsor by Oncoceutics, INC


Eligibility of study

You may be eligible for this study if you meet the following criteria:

  • Conditions: glioma
  • Age: 18 years - 99 years
  • Gender: All

Adults Subjects (age 18 or older) with a histone H3 K27M mutant glioma that has progressed after radiation therapy.

Updated on 04 Aug 2024. Study ID: 832987

Find a site

We have submitted the contact information you provided to the research team at {{SITE_NAME}}. A copy of the message has been sent to your email for your records.
Would you like to be notified about other trials? Sign up for Patient Notification Services.
Sign up

Send a message

Enter your contact details to connect with study team

Investigator Avatar

Primary Contact

First name*
Last name*
Email*
Phone number*
Preferred way of contact
Race
Ethnicity
Other language

Interested in the study

Select a study center that’s convenient for you, and get in touch with the study team.

Contact a study center